United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond Sells 7,800 Shares

United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond sold 7,800 shares of the stock in a transaction on Monday, October 28th. The stock was sold at an average price of $350.00, for a total value of $2,730,000.00. Following the transaction, the chief financial officer now owns 6,978 shares of the company’s stock, valued at approximately $2,442,300. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

James Edgemond also recently made the following trade(s):

• On Monday, October 21st, James Edgemond sold 7,782 shares of United Therapeutics stock. The shares were sold at an average price of $366.99, for a total transaction of $2,855,916.18.
• On Monday, October 14th, James Edgemond sold 7,792 shares of United Therapeutics stock. The shares were sold at an average price of $355.88, for a total transaction of $2,773,016.96.
• On Monday, October 7th, James Edgemond sold 7,794 shares of United Therapeutics stock. The stock was sold at an average price of $355.54, for a total transaction of $2,771,078.76.
• On Monday, September 30th, James Edgemond sold 7,792 shares of United Therapeutics stock. The stock was sold at an average price of $358.62, for a total value of $2,794,367.04.
• On Monday, September 23rd, James Edgemond sold 7,796 shares of United Therapeutics stock. The shares were sold at an average price of $354.04, for a total value of $2,760,095.84.
• On Monday, September 9th, James Edgemond sold 7,802 shares of United Therapeutics stock. The shares were sold at an average price of $345.41, for a total value of $2,694,888.82.
• On Tuesday, September 3rd, James Edgemond sold 7,785 shares of United Therapeutics stock. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $352.80 on Wednesday. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $377.03. The firm’s 50 day moving average is $354.14 and its two-hundred day moving average is $314.95. The firm has a market capitalization of $15.65 billion, a P/E ratio of 16.68, a P/E/G ratio of 1.27 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The company had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company’s quarterly revenue was up 19.8% on a year-over-year basis. During the same period last year, the business earned $5.24 earnings per share. Research analysts forecast that United Therapeutics Co. will post 24.72 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Jefferies Financial Group upped their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. Oppenheimer boosted their target price on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. TD Cowen increased their price target on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Finally, Wells Fargo & Company boosted their price objective on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $361.33.

Institutional Trading of United Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. ClariVest Asset Management LLC grew its stake in United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after buying an additional 42 shares during the last quarter. V Square Quantitative Management LLC purchased a new position in shares of United Therapeutics during the second quarter worth approximately $30,000. Innealta Capital LLC acquired a new position in shares of United Therapeutics in the 2nd quarter valued at $33,000. USA Financial Formulas purchased a new stake in United Therapeutics in the 3rd quarter valued at $33,000. Finally, Values First Advisors Inc. acquired a new stake in United Therapeutics during the 3rd quarter worth $90,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.